Literature DB >> 11535342

Sterilizing immunity against experimental Helicobacter pylori infection is challenge-strain dependent.

H Kleanthous1, T J Tibbitts, H L Gray, G A Myers, C K Lee, T H Ermak, T P Monath.   

Abstract

The development of a murine model of Helicobacter pylori infection through serial in vivo passage of candidate strains has enabled a quantitative assessment of vaccine efficacy. In this study we compare infection with and protection against challenge from both CagA(+) type I, and CagA(-) type II in vivo adapted isolates. In vivo passage of a type II H. pylori isolate resulted in a highly infectious strain (X47-2AL), capable of reproducibly infecting mice to high density (10(7) CFU/g of gastric tissue). Similarly adapted type I strains were found to colonize mice at a significantly lower level (10(4)-10(5) CFU/g tissue). Mucosal immunization with recombinant urease (rUre) significantly protected animals against both types. Protection against X47-2AL was characterized by a > or =100-fold (or 2 log) reduction in bacterial density. However, the presence of a residual infection highlighted the inability to achieve sterilizing immunity against this strain. The level of protection appeared independent of challenge dose, and was stable for up to 6 months, all animals exhibiting a low-level residual infection that did not recrudesce with time. Similarly immunized mice challenged with isolates representing the residual infection were also protected, confirming that they did not represent a sub-population of H. pylori that could escape immunity. Immunization and challenge studies with type I adapted-isolates, demonstrated a similar 2-3 log reduction in the bacterial burden, but that in this instance resulted in sterilizing immunity. These results suggest varied specificity for the murine host by different Helicobacter strains that can influence the outcome of both infection and immunity.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11535342     DOI: 10.1016/s0264-410x(01)00248-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Iron-sulfur protein maturation in Helicobacter pylori: identifying a Nfu-type cluster carrier protein and its iron-sulfur protein targets.

Authors:  Stéphane L Benoit; Ashley A Holland; Michael K Johnson; Robert J Maier
Journal:  Mol Microbiol       Date:  2018-03-30       Impact factor: 3.501

Review 2.  Vaccinating against Helicobacter pylori in the developing world.

Authors:  Shamila Zawahir; Steven J Czinn; John G Nedrud; Thomas G Blanchard
Journal:  Gut Microbes       Date:  2013-11-06

3.  Helicobacter Catalase Devoid of Catalytic Activity Protects the Bacterium against Oxidative Stress.

Authors:  Stéphane L Benoit; Robert J Maier
Journal:  J Biol Chem       Date:  2016-09-07       Impact factor: 5.157

4.  Motility of urease-deficient derivatives of Helicobacter pylori.

Authors:  Shumin Tan; Douglas E Berg
Journal:  J Bacteriol       Date:  2004-02       Impact factor: 3.490

5.  Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis.

Authors:  Frank Sommer; Henning Wilken; Gerhard Faller; Michael Lohoff
Journal:  Infect Immun       Date:  2004-02       Impact factor: 3.441

6.  Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations.

Authors:  Jennifer M Taylor; Melanie E Ziman; Julie Fong; Jay V Solnick; Michael Vajdy
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

7.  Clearance of Helicobacter pylori Infection and Resolution of Postimmunization Gastritis in a Kinetic Study of Prophylactically Immunized Mice.

Authors:  Christine A Garhart; Raymond W Redline; John G Nedrud; Steven J Czinn
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

8.  In silico experiment with an-antigen-toll like receptor-5 agonist fusion construct for immunogenic application to Helicobacter pylori.

Authors:  Mohamad Ali Haghighi; Ashraf Mohabati Mobarez; Ali Hatef Salmanian; Mohamad Moazeni; Mohamad Reza Zali; Mehdi Sadeghi; Jafar Amani
Journal:  Indian J Hum Genet       Date:  2013-01

9.  The redefinition of Helicobacter pylori lipopolysaccharide O-antigen and core-oligosaccharide domains.

Authors:  Hong Li; Tiandi Yang; Tingting Liao; Aleksandra W Debowski; Hans-Olof Nilsson; Alma Fulurija; Stuart M Haslam; Barbara Mulloy; Anne Dell; Keith A Stubbs; Barry J Marshall; Mohammed Benghezal
Journal:  PLoS Pathog       Date:  2017-03-17       Impact factor: 6.823

10.  Leptin, CD4(+) T(reg) and the prospects for vaccination against H. pylori infection.

Authors:  Anna K Walduck; Dorit Becher
Journal:  Front Immunol       Date:  2012-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.